NCT05605470 - Immunogenicity and Safety of ChulaCov19 BNA159 and ChulaCov19 BNA159.2 Vaccines as a Booster Dose in Adults | Biotech Hunter

Enrollment

150

Participants

Timeline

Start Date

January 19, 2023

Primary Completion Date

July 15, 2024

Study Completion Date

November 18, 2024

Conditions

COVID-19, SARS CoV 2 Infection

Interventions

BIOLOGICAL

ChulaCov19 BNA159 vaccine (50 mcg)

Single dose of ChulaCov19 BNA159 vaccine 0.5 ml will be given by IM at Day 1

BIOLOGICAL

Pfizer/BNT vaccine (30 mcg)

Single dose of Pfizer/BNT vaccine 0.3 ml will be given by IM at Day 1

BIOLOGICAL

COMVIGEN (ChulaCov19 BNA159.2) vaccine (50 mcg)

Single dose of COMVIGEN vaccine 0.5 ml will be given by IM at Day 1

Trial Locations (5)

The Children's Hospital at Westmead Sydney, Westmead

Paratus Clinical Research Western Sydney, Blacktown

Paratus Clinical Research Central Coast, Kanwal

Paratus research Canberra Clinic, Bruce

Paratus Clinical Research- Brisbane Clinic, Albion